Literature DB >> 27228123

Bronchiolitis: Analysis of 10 consecutive epidemic seasons.

Giulia Cangiano1, Raffaella Nenna1, Antonella Frassanito1, Melania Evangelisti1, Ambra Nicolai1, Carolina Scagnolari2, Alessandra Pierangeli2, Guido Antonelli2, Paola Papoff1, Laura Petrarca1, Paolo Capocaccia1, Corrado Moretti1, Fabio Midulla1.   

Abstract

Bronchiolitis is the leading cause of hospitalization in infants under 12 months. Our aims were to analyze epidemiological characteristics of infants with bronchiolitis over 10 consecutive seasons and to evaluate whether there are any clinical differences between infants hospitalized for bronchiolitis during epidemic peak months and infants in non-peak months. We enrolled consecutive enrolled 723 previously healthy term infants hospitalized at the Paediatric Emergency Department, "Sapienza" University of Rome over the period 2004-2014. Fourteen respiratory viruses were detected from nasopharyngeal aspirates by molecular methods. Clinical and demographic data were extracted from clinical charts. Viruses were detected in 351 infants (48.5%): RSV in 234 (32.4%), RV in 44 (6.1%), hBoV in 11 (1.5%), hMPV in 12 (1.6%), co-infections in 39 (5.4%), and other viruses in 11 (1.5%). Analyzing the 10 epidemic seasons, we found higher incidence for bronchiolitis every 4 years with a peak during the months December-January. Infants hospitalized during peak months had lower family history for asthma (P = 0.003), more smoking mothers during pregnancy (P = 0.036), were slightly higher breastfed (0.056), had lower number of blood eosinophils (P = 0.015) and had a higher clinical severity score (P = 0.017). RSV was detected mostly during peak months, while RV was equally distributed during the seasons. We found some variations in bronchiolitis incidence during epidemics, and discriminative characteristics in infants hospitalized for bronchiolitis during peak months and in non-peak months, that might reflect two different populations of children. Pediatr Pulmonol. 2016;51:1330-1335.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  bronchiolitis; epidemics; infants; virus

Mesh:

Year:  2016        PMID: 27228123      PMCID: PMC7167938          DOI: 10.1002/ppul.23476

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


INTRODUCTION

Acute bronchiolitis is the most common lower respiratory tract infection in infants and the leading cause of hospitalization in this group of patients.1 Bronchiolitis is diagnosed mostly in winter, in particular between October and May during respiratory viruses circulation periods. It is well known that the number of infants with bronchiolitis rapidly increases from the beginning of the epidemic, it reaches a peak with a plateau during the 2–3 central months and then rapidly decreases during the last months. The identification of a virus is higher during the peak months of the epidemic and it is lower at the beginning and at the end, but it is not clear whether patients who have bronchiolitis during the peak months have different demographic and clinical characteristics, comparing to those who have bronchiolitis during the non‐peak months.1, 2 Furthermore, it has been shown that also the number of patients with bronchiolitis may change from 1 year to the other probably due to viruses’ characteristics and the immunological status of the patients.3 Because of the conflict that exists in the definition, a more homogenous material, following strict inclusion criteria are needed. The evident relationship between respiratory syncytial virus (RSV) and bronchiolitis has been widely described in the last decades.4 Recently, with the improvement in viral identification techniques, it has been showed that also other respiratory viruses are associated with this disease, but the clinical characteristics of infants with bronchiolitis from other respiratory viruses is still controversial.5, 6, 7, 8 The main purpose of our study was to describe the prevalence and the epidemiology of 14 respiratory viruses in previously healthy full term infants hospitalized for bronchiolitis during 10 consecutive annual epidemic periods. In addition we tested the hypothesis that infants hospitalized during the peak months of bronchiolitis epidemics were different from those hospitalized during the non‐peak months, by comparing demographic and clinical characteristics in those two groups of infants.

MATERIALS AND METHODS

Patients

We prospectively enrolled 723 consecutive infants (median age 2.13 months, range [0.23–11.97], 395 [54.6%] male) hospitalized for bronchiolitis in the Paediatric Emergency Department of “Sapienza” University of Rome during 10 consecutive annual epidemic periods from October to May, from the years 2004 to 2014. Acute bronchiolitis was clinically defined as the first episode of acute lower respiratory tract infection in infants less than 12 months, characterized by the acute onset of cough, tachypnoea, retraction, and diffuse crackles on chest auscultation.9 Exclusion criteria were prematurity and underlying chronic diseases, such as cystic fibrosis, interstitial lung disease, congenital heart disease, and immunodeficiency. Detailed demographic characteristics were obtained from parents with a structured questionnaire; clinical and laboratory data were extracted from patients’ medical files. Studied variables included age, gender, breast feeding history, family smoking habit, school attendance by siblings, family history for asthma and atopy, blood eosinophil count, chest radiological findings, and number of days of hospitalization. In addition, a clinical severity score ranging from 0 to 8 was assigned to each infant on admission in the hospital according to respiratory rate, arterial oxygen saturation on room air, presence of retractions, and ability to tolerate oral feeding.10 Considering the high prevalence of bronchiolitis during specific months of the years, we divided our patients in infants who were hospitalized during the peak months and infants who were hospitalized during the non‐peak months. For peak months, we empirically considered the 3 central months of each epidemic season (including at least 75% of the population/year). The parents of all infants were asked to participate in the study and gave informed consents. The study was approved by the research and ethics committee of the Hospital.

Virus Detection

To detect respiratory viruses, we collected nasopharyngeal aspirates within the first day of hospitalization using 3 ml of sterile isotonic solution injected into each nostril and aspirated back with a syringe. We sent the samples on ice to the virology laboratory to analyze: 200 µl of respiratory specimens were used to extract nucleic acid with the total nucleic acid isolation kit (Roche Diagnostics, Mannheim, Germany), eluting with 50 ml of the supplied elution buffer. A panel of either reverse transcriptase (RT) or nested PCR assays has been used to detect 14 respiratory viruses: RSV, Rhinoviruses (RV), influenza virus (IV) A and B, human Coronavirus (hCoV) OC43, 229E, NL‐63 and HUK1, Adenovirus, RV, Parainfluenza virus (PIV) 1–3, and Human Metapneumovirus (hMPV).11 Human Bocavirus (hBoV) was detected with a different PCR method used by Allander et al.12 Rhinoviruses were detected targeting the 5′ UTR region, well conserved among Rhinoviruses and respiratory Enteroviruses so that they are not distinguished by this test. A subset of RV‐positive samples was amplified and sequenced in less conserved regions (VP4‐VP2) and 1 out of 38 resulted to be Enterovirus 68.

Statistical Analysis

For statistical reasons, we decide to consider occasional viruses all the viruses found with incidence lower than 1% in the 10 years. Continuous variables values were expressed as mean ± SD or median and range and categorical variables as number and percentages. A one‐way analysis of variance (ANOVA) and Student's t‐test were used for the comparison of continues variables. The Mann–Whitney and Kruskal–Wallis tests were used to analyze categorical independent variables. We considered statistically significant a P < 0.05. Statistical analysis was performed using the SPSS Software (version 21.0; SPSS Inc., Chicago, IL).

RESULTS

Only 6.5% of parents approached declined to take part to the study. Among the 723 previously healthy, term, infants consecutively hospitalized for bronchiolitis, we were able to identified 391 viruses from the nasopharyngeal aspirates of 351 children. RSV was identified in 234 infants, RV in 44, hBoV in 11, hMPV in 12, PIV in 5 (four PIV 3 and one PIV 1), hCoV in 2, IV in 4; coinfections were identified in 39 infants (RSV‐RV n = 13, RSVhBoV n = 13, RSVInfluenza n = 2, RSVhMPV n = 2, RSV‐PIV 3 n = 1, hBoVhMPV n = 1, hBoV‐PIV 1 n = 1, RV‐hMPV n = 4, RV‐PIV 3 n = 1, RSV‐RV‐hMPV n = 1). Comparing clinical characteristics of bronchiolitis from different viruses, we found that RSV patients were significantly younger (vs. hBoV P < 0.001) and had a higher severity score with respect to other groups (P < 0.041). A higher number of blood eosinophils was found in RV patients than in other groups (P < 0.014). No differences were found in terms of length of hospitalization, demographic data, and clinical severity score between different viruses’ groups, including coinfected infants. Considering the 10 epidemics, we observed a significantly higher number of infants hospitalized with bronchiolitis in the 3rd (n = 102) and 7th (n = 105) epidemics (2006–2007 and 2010–2011) than in the 4th (n = 47) and 8th (n = 73) epidemics (2007–2008 and 2011–2012) (P < 0.001) (Fig. 1a).
Figure 1

(a) Number of infants hospitalized for bronchiolitis over 10 epidemics. (b) Number of infants hospitalized for bronchiolitis by infection type (RSV, RV, hBoV, hMPV, and coinfections) during the 10 epidemics divided by month.

(a) Number of infants hospitalized for bronchiolitis over 10 epidemics. (b) Number of infants hospitalized for bronchiolitis by infection type (RSV, RV, hBoV, hMPV, and coinfections) during the 10 epidemics divided by month. Most of the patients were recruited in the winter months, especially in December–February and, analyzing viruses’ detection, we found that RSV follows the temporal trend of the disease, while other viruses were equally distributed over the year (Fig. 1b). Comparing the epidemiology over the 10 years, a variability of the month with the higher incidence, even within the winter months, was found. Particularly, the month with a higher number of hospitalization for bronchiolitis was January in seven epidemics (3rd–5th, 7th–10th) and February in three (1st, 2nd, and 6th) (Fig. 2).
Figure 2

Distribution of identified viruses in infants hospitalized for bronchiolitis over the 10 epidemics without (a) and with (b) negative infants.

Distribution of identified viruses in infants hospitalized for bronchiolitis over the 10 epidemics without (a) and with (b) negative infants. Dividing infants according to the hospitalization during the peak months or non‐peak months, we found some statistically significant differences in terms of risk factors for respiratory diseases. The 596 infants hospitalized in the peak months had less frequently both parents with asthma (P = 0.003), had higher maternal smoke during pregnancy (P = 0.036) and were slightly higher breastfed (P = 0.056). Moreover, children in the peak months had lower number of eosinophils (P = 0.015) and had a higher severity score (P = 0.017) than infants in non‐peak months. Analyzing viruses’ detection, RSV was more frequently detected in peak months than non‐peak months, differing from RV (P = 0.029). No differences were found for other clinical variables evaluated (Table 1).
Table 1

Demographic and Clinical Variables of Infants Hospitalized for Bronchiolitis, During Peak and Non‐Peak Months

VariablesPeak‐months (n = 596)Non‐peak months (n = 127) P
Sex (male)54%57.5%ns
Age (days)77.45 ± 58.4983.34 ± 56.14ns
Gestational age (weeks)38.81 ± 1.2638.84 ± 1.10ns
Family history of asthma21.3%25.2%ns
Both parents with positive history of asthma0.3%3.8%0.003
Family history of atopy34.4%33.9%ns
Presence of passive smoke46.3%43.7%ns
Smoking during pregnancy9.8%4%0.036
Caesarian section51.8%46.8%ns
Breastfeeding at recovery78%70.1%0.056
Chest x‐ray consolidation55.2%55.8%ns
WBC11,589 ± 4,65711,821 ± 5,591ns
Blood eosinophils 1 80 (0–1,412)120 (0–1,315)0.015
C‐reactive protein (mg/dl)0.44 (0–16.98)0.3 (0–7.18)ns
Severity score:
Time 03.31 ± 2.082.79 ± 1.980.017
Time 24 hr2.28 ± 1.831.55 ± 1.560.001
Time 48 hr1.59 ± 1.610.96 ± 1.120.001
Days of hospitalization5.13 ± 2.444.75 ± 1.79ns
Negative for viruses300 (50.3%)72 (56.7%)ns
RSV only204 (34.2%)30 (23.6%)0.022
RV only32 (5.4%)12 (9.4%)0.067
Bocavirus11 (1.8%)0ns
Metapneumovirus8 (1.3%)4 (3.1%)ns
Others8 (1.3%)3 (2.4%)ns
Coinfections33 (5.5%)6 (4.7%)ns

Data were expressed as mean ± SD.

Peak months were January–March for the 1st, 2nd, 6th epidemic seasons and December–February for the 3rd–5th, 7th–10th epidemic seasons.

Data were expressed as median and range.

Demographic and Clinical Variables of Infants Hospitalized for Bronchiolitis, During Peak and Non‐Peak Months Data were expressed as mean ± SD. Peak months were January–March for the 1st, 2nd, 6th epidemic seasons and December–February for the 3rd–5th, 7th–10th epidemic seasons. Data were expressed as median and range.

DISCUSSION

With the present study, we examined the epidemiology and the characteristics of acute bronchiolitis, in infants hospitalized in a single Italian pediatric medical center, over 10 consecutive epidemic seasons. The peak of hospitalization for bronchiolitis tended to come early to January and showed an increase of cases every 4 years. RSV was confirmed as the most common agent of bronchiolitis, followed by RV, hBoV, and hMPV; coinfections have been detected in 5.4% of children. In our study, we confirmed that RSV infection was present in younger and more clinically severe infants, while infants with RV had higher number of blood eosinophils. Finally, differences in terms of demographic and clinical characteristics have been found between infants hospitalized for bronchiolitis during the peak months and ones during non‐peak months. One strength of our study is that we included only infants with a well‐characterized definition of bronchiolitis (infants younger than 12 months presenting with their first episode of lower respiratory infection, who had diffuse crackles on auscultation). Otherwise, the American Pediatric Academy defines bronchiolitis as the first episode of acute viral wheeze occurring in infants less than 2 years.1 In order to exclude infants with virus associated episodes of wheezing, having wheezing alone was not considered sufficient for inclusion in the study.10 Comparing hospitalization for bronchiolitis during different years, we found a peak of incidence in the 3rd and 7th seasons in respect to the subsequent year indicating that respiratory virus circulation apparently increase every 4 years. Alternating circulation of RSV types A and B could explain different rates of hospitalization in different epidemic seasons, but unfortunately, as stated below as a study limitation, we did not test for viruses’ subtypes along the whole study period. Moore et al. studied duration of immunity after RSV infection assuming the need of a sufficient number of infected people at the same time to gain population immunity also considering that immunity could wane several months before the onset of a subsequent RSV season. Differences in viral circulation during the years could be linked to the circulation of different viral genotypes or, than, to the “herd immunity.”8, 13 In fact, the spread of a new RSV A subtype (ON1) has been recently demonstrated in Rome.14 Our finding of an anticipation of the month with the higher incidence of bronchiolitis (December or January instead of March) could be linked to changes in climatic conditions, such as temperature or humidity, and to air pollution modification over different years.15 This fact could influence viral spread along with predisposition of patients to respiratory infection. Comparing bronchiolitis from different viruses in 10 consecutive seasons, we confirmed RSV as more severe agent affecting younger infants. Moreover, while RV was equally distributed during the year, most of RSV was detected during winter months, strongly correlating with bronchiolitis incidence trend, as other studies have already shown.16 We think that this fact may be caused by climate factors, such as temperature, air pressure, and pollution modifications could modulate even the seasonality of viruses, as other studies already evidenced.17, 18 In fact, the study by Hervás et al. concluded that the mean temperature and atmospheric pressure were the main factors for RSV activity.18 Observing the distribution of bronchiolitis during the year, we were able to isolate peak and non‐peak months of hospitalization for this disease with some differences between the two populations. An association between peak bronchiolitis, incidence, and clinical severity was found. It could be linked to our finding of higher incidence of RSV in peak months with respect to the non‐peak months. Having both parents with asthma and the number of eosinophils were significantly lower during peak months. These facts may justify the different characteristics of this population hospitalized in a period with lower viruses detection and less severe viral infections. On the other hand, analyzing risk factors for respiratory diseases, infants exposed to maternal smoke during pregnancy were hospitalized more during peak months; this could be linked to modification of respiratory mucosa and subsequent predisposition to viral infection, in particular from RSV in at risk infants. Noakes et al. studied that smoke increases early susceptibility to infection and, then, the subsequent IgA responses.19, 20, 21, 22, 23 Our study has some limitations. First, as we discussed in our previous article,10 although the sensitive and comprehensive PCR method, our virus detection rate was poor. It could be partly due to technical problems related to collecting and storing samples. Otherwise, some of the virus negative cases may be related to undetected pathogens. Finally, we did not test for viruses subtypes. In conclusion, we found some variations in bronchiolitis incidence during epidemics, and discriminative characteristics in infants hospitalized for bronchiolitis during peak months and in non‐peak months that might reflect two different populations of children.

AUTHORS’ CONTRIBUTIONS

Cangiano G: drafting the work and approved the final manuscript as submitted. Frassanito A and Nenna R: interpretation of data for the work and approved the final manuscript as submitted. Evangelisti M, Ambra N, Petrarca L, and Papoff P: acquisition of the data and approved the final manuscript as submitted. Pierangeli A, Scagnolari C, and Antonelli G: performed viral analysis and approved the final manuscript as submitted. Capocaccia P: reevaluated the chest X‐ray. Moretti C: revising the work critically for important intellectual content and approved the final manuscript as submitted. Midulla F: conception and design of the work and approved the final manuscript as submitted.
  21 in total

1.  Health effects of passive smoking. 1. Parental smoking and lower respiratory illness in infancy and early childhood.

Authors:  D P Strachan; D G Cook
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

2.  Diagnosis and management of bronchiolitis.

Authors: 
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

3.  Rapid spread of the novel respiratory syncytial virus A ON1 genotype, central Italy, 2011 to 2013.

Authors:  A Pierangeli; D Trotta; C Scagnolari; M L Ferreri; A Nicolai; F Midulla; K Marinelli; G Antonelli; P Bagnarelli
Journal:  Euro Surveill       Date:  2014-07-03

4.  The effects of maternal smoking on early mucosal immunity and sensitization at 12 months of age.

Authors:  Paul Noakes; Angie Taylor; Jasmine Hale; Liza Breckler; Peter Richmond; Sunalene G Devadason; Susan L Prescott
Journal:  Pediatr Allergy Immunol       Date:  2007-03       Impact factor: 6.377

Review 5.  Correlations between climate factors and incidence--a contributor to RSV seasonality.

Authors:  Julian W Tang; Tze Ping Loh
Journal:  Rev Med Virol       Date:  2013-11-09       Impact factor: 6.989

6.  Acute respiratory illness in the community. Frequency of illness and the agents involved.

Authors:  A S Monto; K M Sullivan
Journal:  Epidemiol Infect       Date:  1993-02       Impact factor: 2.451

7.  Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants.

Authors:  F Midulla; C Scagnolari; E Bonci; A Pierangeli; G Antonelli; D De Angelis; R Berardi; C Moretti
Journal:  Arch Dis Child       Date:  2009-10-11       Impact factor: 3.791

8.  Meteorologic conditions and respiratory syncytial virus activity.

Authors:  Daniel Hervás; Jordi Reina; Juan A Hervás
Journal:  Pediatr Infect Dis J       Date:  2012-10       Impact factor: 2.129

9.  Role of respiratory pathogens in infants hospitalized for a first episode of wheezing and their impact on recurrences.

Authors:  S Bosis; S Esposito; H G M Niesters; G V Zuccotti; G Marseglia; M Lanari; G Zuin; C Pelucchi; A D M E Osterhaus; N Principi
Journal:  Clin Microbiol Infect       Date:  2008-07       Impact factor: 8.067

Review 10.  Newly discovered respiratory viruses: significance and implications.

Authors:  Jeffrey S Kahn
Journal:  Curr Opin Pharmacol       Date:  2007-08-06       Impact factor: 5.547

View more
  22 in total

1.  Early child development: a challenge in China.

Authors:  Jie Shao
Journal:  World J Pediatr       Date:  2019-01-10       Impact factor: 2.764

2.  Changes in Bronchiolitis Incidence During the Last Two Decades in Tampere, Finland: A Retrospective Study.

Authors:  Tytti Vihikangas; Sauli Palmu; Anna-Maija Koivisto; Paula Heikkilä
Journal:  Pediatr Infect Dis J       Date:  2022-07-28       Impact factor: 3.806

Review 3.  The impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?

Authors:  Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Gustavo Nino; Fabio Midulla
Journal:  Paediatr Respir Rev       Date:  2019-04-12       Impact factor: 2.726

4.  Severe bronchiolitis profiles and risk of recurrent wheeze by age 3 years.

Authors:  Orianne Dumas; Kohei Hasegawa; Jonathan M Mansbach; Ashley F Sullivan; Pedro A Piedra; Carlos A Camargo
Journal:  J Allergy Clin Immunol       Date:  2018-09-18       Impact factor: 10.793

5.  Racial and ethnic disparities in bronchiolitis management in freestanding children's hospitals.

Authors:  Aubree C Honcoop; Patricia Poitevien; Ellen Kerns; Brian Alverson; Russell J McCulloh
Journal:  Acad Emerg Med       Date:  2021-06-11       Impact factor: 5.221

6.  Increased severity of respiratory syncytial virus airway infection due to passive smoke exposure.

Authors:  Clemens Maedel; Katharina Kainz; Thomas Frischer; Matthias Reinweber; Angela Zacharasiewicz
Journal:  Pediatr Pulmonol       Date:  2018-07-30

7.  Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy.

Authors:  C Ciarlitto; A C Vittucci; L Antilici; C Concato; C Di Camillo; P Zangari; A Villani
Journal:  Ital J Pediatr       Date:  2019-08-28       Impact factor: 2.638

8.  Human bocavirus in children hospitalized for acute respiratory tract infection in Rome.

Authors:  Laura Petrarca; Raffaella Nenna; Antonella Frassanito; Alessandra Pierangeli; Greta Di Mattia; Carolina Scagnolari; Fabio Midulla
Journal:  World J Pediatr       Date:  2019-11-27       Impact factor: 2.764

9.  Cost-effectiveness analysis of phenotypic-guided versus guidelines-guided bronchodilator therapy in viral bronchiolitis.

Authors:  Carlos E Rodriguez-Martinez; Gustavo Nino; Jose A Castro-Rodriguez; Geovanny F Perez; Monica P Sossa-Briceño; Jefferson A Buendia
Journal:  Pediatr Pulmonol       Date:  2020-10-20

10.  Human respiratory syncytial virus and hospitalization in young children in Italy.

Authors:  Parvanè Kuhdari; Federica Brosio; Cristina Malaventura; Armando Stefanati; Andrea Orsi; Giancarlo Icardi; Giovanni Gabutti
Journal:  Ital J Pediatr       Date:  2018-05-04       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.